Evidence map›Paper›PMID 28886122›Full record

ArticlePloS one2017

Alteration of Endothelin 1, MCP-1 and Chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation.

K Lackermair, S Clauss, T Voigt, I Klier, C Summo, B Hildebrand, T Nickel, H L Estner, S Kääb, R Wakili and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The Role of Major Biomarkers of Stress in Atrial Fibrillation: A Literature Review.The Journal of innovations in cardiac rhythm management · 2023
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

K LackermairDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
S ClaussDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
T VoigtDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
I KlierDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
C SummoDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
B HildebrandDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
T NickelDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
H L EstnerDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
S KääbDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
R WakiliDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
U Wilbert-LampenDepartment of Medicine I, Klinikum Grosshadern, University of Munich (LMU), Munich, Germany.
Ludwig-Maximilians-Universität München · DELMU Klinikum · DEWest German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relation between arrhythmias and stress is known. The aim of our current study was to elucidate whether plasma levels of previously described stress parameters are altered in highly symptomatic patients with atrial fibrillation (AF) per se and in patients undergoing ablation therapy by pulmonary vein isolation (PVI).

methods96 patients with AF undergoing PVI were recruited. Plasma levels of Endothelin-1 (ET-1), MCP-1 and Chromogranin-A (CGA) were measured before and three months after ablation completed with clinical follow-up with respect to AF recurrence. Additionally, we examined 40 healthy age- and sex-matched volunteers as a reference.

resultsSymptomatic AF patients showed increased levels of ET-1 compared to healthy controls (2.62pg/ml vs. 1.57pg/ml; p<0.01). Baseline levels of ET-1 were higher in patients presenting with AF after PVI (2.96pg/ml vs. 2.57pg/ml;p = 0.02). The temporal comparison revealed decreased ET-1 levels in patients without (2.57pg/ml vs. 2.33pg/ml; p<0.01) and unchanged ET-1 levels in patients with AF after PVI. Baseline MCP-1 was increased in AF patients vs. controls (268pg/ml vs. 227 pg/ml; p = 0.03). Both groups, with and without AF after PVI, showed an increase of MCP-1 compared to baseline (268pg/ml vs. 349pg/ml;p<0.01; 281pg/ml vs. 355pg/ml;p = 0.03). CGA was lower in AF patients compared to healthy controls (13.8ng/ml vs. 25.6ng/ml;p<0.01). Over time patients without AF after PVI showed an increase of CGA (14.2ng/ml vs. 20.7ng/ml;p<0.01). No change was observed in patients with AF after PVI.

conclusionOur study demonstrated dysregulated levels of ET-1, MCP-1 and CGA in symptomatic AF patients. We could demonstrate an association between ET-1 to presence or absence of AF. Furthermore, we could show that a decrease of ET-1 as well as an increase of CGA after PVI, representing a trend towards control cohort levels, were both associated with restoration of sinus rhythm. These results provide new insights into the role of stress-related biomarkers in AF and AF treatment by ablation therapy.

Indexed as

AgedAtrial FibrillationBiomarkersChemokine CCL2Chromogranin AEndothelin-1HumansMiddle AgedPulmonary VeinsStress, PhysiologicalBiomarkersCCL2 protein, humanChemokine CCL2Chromogranin AEndothelin-1

Identifiers

PMID28886122
PMCPMC5590904
OpenAlexW2751131212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.